Pancreatic cancer: gene therapy approaches and gene delivery systems

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Mancuso A, Calabrò F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006;58(3):231-41
   PubMed Web of Science ®Google Scholar
• Garcea G, Dennison AR, Pattenden CJ, Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature JOP 2008;9(2):99-132
   Google Scholar
• Huguet F, Girard N, Guerche CS, Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27(13):2269-77
   PubMed Web of Science ®Google Scholar
• Klautke G, Brunner TB. Radiotherapy in pancreatic cancer. Strahlenther Onkol 2008;184(11):557-64
   PubMed Web of Science ®Google Scholar
• Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer 2008;112(2):243-9
   PubMed Web of Science ®Google Scholar
• Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006;73(3):485-92
   PubMed Web of Science ®Google Scholar
• Costa ET, Forti FL, Matos TG, Fibroblast growth factor 2 restrains Ras-driven proliferation of malignant cells by triggering RhoA-mediated senescence. Cancer Res 2008;68(15):6215-23
   PubMed Web of Science ®Google Scholar
• Fischbach MA, Settleman J. Regulation of the nucleotide state of oncogenic ras proteins by nucleoside diphosphate kinase. Methods Enzymol 2006;407:33-45
   PubMed Web of Science ®Google Scholar
• Dreissigacker U, Mueller MS, Unger M, Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal 2006;18(8):1156-68
   PubMed Web of Science ®Google Scholar
• Shields JM, Pruitt K, McFall A, Understanding Ras: ‘it ain't over 'til it's over'. Trends Cell Biol 2000;10(4):147-54
   PubMed Web of Science ®Google Scholar
• Fryzek JP, Garabrant DH, Schenk M, The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 2006;37(4):139-45
   PubMedGoogle Scholar
• Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. Int J Gastrointest Cancer 2005;35(1):33-41
   PubMedGoogle Scholar
• Wei S, Liang Z, Gao J, Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroenterol Hepatol 2005;20(1):67-72
   PubMed Web of Science ®Google Scholar
• Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2(12):897-909
   PubMed Web of Science ®Google Scholar
• Koliopanos A, Avgerinos C, Paraskeva C, Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008;7(4):345-56
   PubMed Web of Science ®Google Scholar
• Minamoto T. Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions. Methods Mol Biol 2005;291:263-78
   PubMedGoogle Scholar
• Shichinohe T, Senmaru N, Furuuchi K, Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 1996;66(2):125-30
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Shichinohe T, Senmaru N, The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7(6):518-26
   PubMed Web of Science ®Google Scholar
• Aoki K, Yoshida T, Matsumoto N, Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 1997;20(2):251-8
   PubMed Web of Science ®Google Scholar
• Miura Y, Ohnami S, Yoshida K, Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett 2005;218(1):53-62
   PubMed Web of Science ®Google Scholar
• Kijima H, Scanlon KJ. Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol Biotechnol 2000;14(1):59-72
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Kijima H, Hori S, Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 2000;7(3):373-83
   PubMed Web of Science ®Google Scholar
• Kijima H, Yamazaki H, Nakamura M, Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer. Int J Oncol 2004;24(3):559-64
   PubMed Web of Science ®Google Scholar
• Chen LM, Le HY, Qin RY, Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol 2005;11(6):831-8
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Dong JH, Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette. World J Gastroenterol 2005;11(13):2026-31
   PubMed Web of Science ®Google Scholar
• He W, Parker R. Functions of Lsm proteins in mRNA degradation and splicing. Curr Opin Cell Biol 2000;12(3):346-50
   PubMed Web of Science ®Google Scholar
• Schweinfest CW, Graber MW, Chapman JM, CaSm: an Sm-like protein that contributes to the transformed state in cancer cells. Cancer Res 1997;57(14):2961-5
   PubMed Web of Science ®Google Scholar
• Kelley JR, Brown JM, Frasier MM, The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery 2000;128(2):353-60
   PubMed Web of Science ®Google Scholar
• Santamariña M, Hernández G, Zalvide J. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status. Cell Cycle 2008;7(13):1962-72
   PubMed Web of Science ®Google Scholar
• Cánepa ET, Scassa ME, Ceruti JM, INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007;59(7):419-26
   PubMed Web of Science ®Google Scholar
• Ashizawa S, Nishizawa H, Yamada M, Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression. J Biol Chem 2001;276(14):11362-70
   PubMed Web of Science ®Google Scholar
• Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57(11):2140-3
   PubMed Web of Science ®Google Scholar
• Attri J, Srinivasan R, Majumdar S, Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol 2005;5:22. Published online 28 June 2005, doi:10.1186/1471-230X-5-22
   PubMed Web of Science ®Google Scholar
• Sato N, Ueki T, Fukushima N, Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002;123(1):365-72
   PubMed Web of Science ®Google Scholar
• Hruban RH, Goggins M, Kern SE. Molecular genetics and related developments in pancreatic cancer. Curr Opin Gastroenterol 1999;15(5):404-9
   PubMed Web of Science ®Google Scholar
• Calbó J, Marotta M, Cascalló M, Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 2001;8(10):740-50
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Shirasawa H, Sashiyama H, P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999;5(12):4182-5
   PubMed Web of Science ®Google Scholar
• Kastanos E, Hjiantoniou E, Phylactou LA. Restoration of protein synthesis in pancreatic cancer cells by trans-splicing ribozymes. Biochem Biophys Res Commun 2004;322(3):930-4
   PubMed Web of Science ®Google Scholar
• Tarapore P, Horn HF, Tokuyama Y, Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene 2001;20(25):3173-84
   PubMed Web of Science ®Google Scholar
• Xie G, Habbersett RC, Jia Y, Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Oncogene 1998;16(6):721-36
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Galluzzi L, p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. Cell Cycle 2009;8(9):1380-5
   PubMed Web of Science ®Google Scholar
• Taii A, Hamada S, Kataoka K, Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. Pancreas 2009;38(2):e60-7
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Aguirre AJ, Chu GC, Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103(15):5947-52
   PubMed Web of Science ®Google Scholar
• Hruban RH, Goggins M, Kern SE. Molecular genetics and related developments in pancreatic cancer. Curr Opin Gastroenterol 1999;15(5):404-9
   PubMed Web of Science ®Google Scholar
• Cascalló M, Mercadé E, Capellà G, Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther 1999;6(5):428-36
   PubMed Web of Science ®Google Scholar
• Bouvet M, Bold RJ, Lee J, Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5(8):681-8
   PubMed Web of Science ®Google Scholar
• Hwang RF, Gordon EM, Anderson WF, Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998;124(2):143-50
   PubMed Web of Science ®Google Scholar
• Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16(9):1016-27
   PubMed Web of Science ®Google Scholar
• Habbe N, Koorstra JB, Mendell JT, MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009;8(4):340-6
   PubMed Web of Science ®Google Scholar
• Greither T, Grochola L, Udelnow A, Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours is associated with poorer survival. Int J Cancer 2009; published online: 23 Jun 2009, doi: 10.1002/ijc.24687
   Google Scholar
• Dillhoff M, Liu J, Frankel W, MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008;12(12):2171-6
   PubMed Web of Science ®Google Scholar
• Lanuti M, Gao GP, Force SD, Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999;10(3):463-75
   PubMed Web of Science ®Google Scholar
• Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007;28(1):4-41
   PubMed Web of Science ®Google Scholar
• Wang J, Lu XX, Chen DZ, Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J Gastroenterol 2004;10(3):400-3
   PubMed Web of Science ®Google Scholar
• Mäkinen K, Loimas S, Wahlfors J, Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2000;2(5):361-7
   PubMed Web of Science ®Google Scholar
• Block A, Chen SH, Kosai K, Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997;15(1):25-34
   PubMed Web of Science ®Google Scholar
• Fogar P, Greco E, Basso D, Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol 2003;29(9):721-30
   PubMedGoogle Scholar
• Greco E, Fogar P, Basso D, Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas 2002;25(2):e21-9
   PubMedGoogle Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171-9
   PubMed Web of Science ®Google Scholar
• Li ZS, Pan X, Xu GM, Killing effects of cytosine deaminase gene mediated by adenovirus vector on human pancreatic cancer cell lines in vitro. Hepatobiliary Pancreat Dis Int 2003;2(1):147-51
   PubMedGoogle Scholar
• Evoy D, Hirschowitz EA, Naama HA, In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997;69(1):226-31
   PubMed Web of Science ®Google Scholar
• Fogar P, Navaglia F, Basso D, Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer. Pancreas 2007;35(3):224-31
   PubMed Web of Science ®Google Scholar
• McNeish IA, Green NK, Gilligan MG, Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998;5(8):1061-9
   PubMed Web of Science ®Google Scholar
• Karle P, Müller P, Renz R, Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 1998;451:97-106
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tomizawa M, Bahar R, A promoter region of midkine gene can activate transcription of an exogenous suicide gene in human pancreatic cancer. Anticancer Res 2002;22(1A):117-20
   PubMed Web of Science ®Google Scholar
• Hiyama E, Kodama T, Shinbara K, Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997;57(2):326-31
   PubMed Web of Science ®Google Scholar
• Zhou JH, Tang B, Liu XL, hTERT-targeted E. coli purine nucleoside phosphorylase gene/6-methylpurine deoxyribose therapy for pancreatic cancer. Chin Med J (Engl) 2007;120(15):1348-52
   PubMed Web of Science ®Google Scholar
• Wang XP, Yazawa K, Yang J, Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg 2004;8(1):98-108
   PubMed Web of Science ®Google Scholar
• Deharvengt S, Wack S, Aprahamian M, Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med 2005;7(5):672-80
   PubMed Web of Science ®Google Scholar
• Hamdollah Zadeh MA, Glass CA, Magnussen A, VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation 2008;15(7):605-14
   PubMed Web of Science ®Google Scholar
• Seo Y, Baba H, Fukuda T, High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88(10):2239-45
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Abe Y, Tsuchida T, Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int J Oncol 2002;21(5):1027-32
   PubMed Web of Science ®Google Scholar
• Büchler P, Reber HA, Ullrich A, Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003;134(5):772-82
   PubMed Web of Science ®Google Scholar
• Hoshida T, Sunamura M, Duda DG, Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002;25(2):111-21
   PubMed Web of Science ®Google Scholar
• Tseng JF, Farnebo FA, Kisker O, Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 2002;132(5):857-65
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Kuba K, Matsumoto K, Date K, HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60(23):6737-43
   PubMed Web of Science ®Google Scholar
• Murakami M, Nagai E, Mizumoto K, Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer 2005;117(1):160-5
   PubMed Web of Science ®Google Scholar
• Saimura M, Nagai E, Mizumoto K, Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther 2002;9(10):799-806
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu J, Lawler J, Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 2007;13(13):3968-76
   PubMed Web of Science ®Google Scholar
• Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12(2):141-61
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274(5286):373-6
   PubMed Web of Science ®Google Scholar
• Mulvihill SWarren R, Venook A, Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther 2001;8(4):308-15
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bedford R, Abbruzzese JL, A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9(2):555-61
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Ganly I, Khuri F, Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res 2000;60(22):6359-66
   PubMed Web of Science ®Google Scholar
• Vasey PA, Shulman LN, Campos S, Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20(6):1562-9
   PubMed Web of Science ®Google Scholar
• Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73(7):5333-44
   PubMed Web of Science ®Google Scholar
• O'Shea CC, Johnson L, Bagus B, Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6(6):611-23
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19(1):2-12
   PubMed Web of Science ®Google Scholar
• Heise C, Hermiston T, Johnson L, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6(10):1134-9
   PubMed Web of Science ®Google Scholar
• Sunamura M, Hamada H, Motoi F, Oncolytic virotherapy as a novel strategy for pancreatic cancer. Pancreas 2004;28(3):326-9
   PubMed Web of Science ®Google Scholar
• Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9(12):967-78
   PubMed Web of Science ®Google Scholar
• Lee JH, Federoff HJ, Schoeniger LO. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J Gastrointest Surg 1999;3(2):127-31
   PubMed Web of Science ®Google Scholar
• McAuliffe PF, Jarnagin WR, Johnson P, Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000;4(6):580-8
   PubMed Web of Science ®Google Scholar
• Kemeny N, Brown K, Covey A, Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006;17(12):1214-24
   PubMed Web of Science ®Google Scholar
• Aghi MK, Chiocca EA. Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 2009;17(1):8-9
   PubMed Web of Science ®Google Scholar
• Etoh T, Himeno Y, Matsumoto T, Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003;9(3):1218-23
   PubMed Web of Science ®Google Scholar
• Hirano S, Etoh T, Okunaga R, Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncol Rep 2009;21(6):1381-4
   PubMed Web of Science ®Google Scholar
• Himeno Y, Etoh T, Matsumoto T, Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int J Oncol 2005;27(4):901-6
   PubMed Web of Science ®Google Scholar
• Hekele A, Dall P, Moritz D, Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:ζ-chimera. Int J Cancer 1996;68(2):232-8
   PubMed Web of Science ®Google Scholar
• Schmidt J, Ryschich E, Sievers E, Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer 2006;106(4):759-64
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Neumann J, Winzen B, Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition. Pancreas 2008;37(3):321-7
   PubMed Web of Science ®Google Scholar
• Schnurr M, Galambos P, Scholz C, Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61(17):6445-50
   PubMed Web of Science ®Google Scholar
• Tang ZH, Qiu WH, Wu GS, The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma. World J Gastroenterol 2002;8(5):908-12
   PubMed Web of Science ®Google Scholar
• Pecher G, Häring A, Kaiser L, Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol Immunother 2002;51(11-12):669-73
   PubMed Web of Science ®Google Scholar
• Lepisto AJ, Moser AJ, Zeh H, A Phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6(B):955-64
   PubMedGoogle Scholar
• Clary BM, Coveney EC, Philip R, Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther 1997;4(2):97-104
   PubMed Web of Science ®Google Scholar
• Pützer BM, Rödicker F, Hitt MM, Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol Ther 2002;5(4):405-12
   PubMed Web of Science ®Google Scholar
• Sangro B, Mazzolini G, Ruiz J, Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22(8):1389-97
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Abrams R, Cameron J, A Phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998;9(13):1951-71
   PubMed Web of Science ®Google Scholar
• Shi XH, Liang ZY, Ren XY, Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 2009;16(3):227-36
   PubMed Web of Science ®Google Scholar
• Ghaneh P, Greenhalf W, Humphreys M, Adenovirus-mediated transfer of p53 and p16INK4a results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001;8(3):199-208
   PubMed Web of Science ®Google Scholar
• Hatanaka K, Suzuki K, Miura Y, Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004;6(10):1139-48
   PubMed Web of Science ®Google Scholar
• Kelley JR, Fraser MM, Schweinfest CW, CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer. Surgery 2001;130(2):280-8
   PubMed Web of Science ®Google Scholar
• Ogura Y, Mizumoto K, Nagai E, Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther 2006;13(5):520-9
   PubMed Web of Science ®Google Scholar
• Freytag SO, Barton KN, Brown SL, Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007;15(9):1600-6
   PubMed Web of Science ®Google Scholar
• Miseki T, Kawakami H, Natsuizaka M, Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist. Cancer Gene Ther 2007;14(1):39-44
   PubMed Web of Science ®Google Scholar
• Deharvengt S, Rejiba S, Wack S, Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 2007;30(6):1397-406
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Gaggar A, Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J Virol 2004;78(18):10009-22
   PubMed Web of Science ®Google Scholar
• Schindler C, Fooks A, Stephenson J, Replication-incompetent adenoviruses as vectors for protective immunization against measles virus infection. Behring Inst Mitt 1994;(95):109-15
   PubMedGoogle Scholar
• Smith-Arica JR, Thomson AJ, Ansell R, Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning Stem Cells 2003;5(1):51-62
   PubMedGoogle Scholar
• Farinha-Arcieri LE, Porchia BM, Carromeu C, Expression and purification of a recombinant adenovirus fiber knob in a baculovirus system. Intervirology 2008;51(3):189-95
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275(5304):1320-3
   PubMed Web of Science ®Google Scholar
• Majhen D, Nemet J, Richardson J, Differential role of alphavbeta3 and alphavbeta5 integrins in internalization and transduction efficacies of wild type and RGD4C fiber-modified adenoviruses. Virus Res 2009;139(1):64-73
   PubMed Web of Science ®Google Scholar
• Soudais C, Boutin S, Hong SS, Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 2000;74(22):10639-49
   PubMed Web of Science ®Google Scholar
• Goldman M, Su Q, Wilson JM. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. Gene Ther 1996;3(9):811-8
   PubMed Web of Science ®Google Scholar
• Palmer DJ, Ng P. Methods for the production of first generation adenoviral vectors. Methods Mol Biol 2008;433:55-78
   PubMedGoogle Scholar
• Gagnoux-Palacios L, Hervouet C, Spirito F, Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J Gene Med 2005;7(9):1178-86
   PubMed Web of Science ®Google Scholar
• Hacker DL, Bertschinger M, Baldi L, Reduction of adenovirus E1A mRNA by RNAi results in enhanced recombinant protein expression in transiently transfected HEK293 cells. Gene 2004;341:227-34
   PubMed Web of Science ®Google Scholar
• Young LS, Searle PF, Onion D, Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006;208(2):299-318
   PubMed Web of Science ®Google Scholar
• Kamen A, Henry O. Development and optimization of an adenovirus production process. J Gene Med 2004;6(Suppl 1):S184-92
   PubMed Web of Science ®Google Scholar
• Crystal RG, Harvey BG, Wisnivesky JP, Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002;13(1):65-100
   PubMed Web of Science ®Google Scholar
• Pearson AS, Koch PE, Atkinson N, Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999;5(12):4208-13
   PubMed Web of Science ®Google Scholar
• Kim M, Zinn KR, Barnett BG, The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002;38(14):1917-26
   PubMed Web of Science ®Google Scholar
• Wesseling JG, Bosma PJ, Krasnykh V, Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther 2001;8(13):969-76
   PubMed Web of Science ®Google Scholar
• Toyoda E, Doi R, Kami K, Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int J Oncol 2008;33(6):1141-7
   PubMed Web of Science ®Google Scholar
• Nony P, Tessier J, Chadeuf G, Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J Virol 2001;75(20):9991-4
   PubMed Web of Science ®Google Scholar
• Van Vliet K, Mohiuddin Y, McClung S, Adeno-associated virus capsid serotype identification: Analytical methods development and application. J Virol Methods 2009;159(2):167-77
   PubMed Web of Science ®Google Scholar
• Nicklin SA, Buening H, Dishart KL, Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001;4(3):174-81
   PubMed Web of Science ®Google Scholar
• Belur LR, Kaemmerer WF, McIvor RS, Adeno-associated virus type 2 vectors: transduction and long-term expression in cerebellar Purkinje cells in vivo is mediated by the fibroblast growth factor receptor 1: bFGFR-1 mediates AAV2 transduction of Purkinje cells. Arch Virol 2008;153(11):2107-10
   PubMed Web of Science ®Google Scholar
• Asokan A, Hamra JB, Govindasamy L, Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 2006;80(18):8961-9
   PubMed Web of Science ®Google Scholar
• Buller RM, Janik JE, Sebring ED, Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981;40(1):241-7
   PubMed Web of Science ®Google Scholar
• Mishra L, Rose JA. Adeno-associated virus DNA replication is induced by genes that are essential for HSV-1 DNA synthesis. Virology 1990;179(2):632-9
   PubMed Web of Science ®Google Scholar
• Leonard JN, Ferstl P, Delgado A, Enhanced preparation of adeno-associated viral vectors by using high hydrostatic pressure to selectively inactivate helper adenovirus. Biotechnol Bioeng 2007;97(5):1170-9
   PubMed Web of Science ®Google Scholar
• Ding W, Zhang L, Yan Z, Intracellular trafficking of adeno-associated viral vectors. Gene Ther 2005;12(11):873-80
   PubMed Web of Science ®Google Scholar
• Cheng H, Wolfe SH, Valencia V, Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8. J Biomed Sci 2007;14(5):585-94
   PubMed Web of Science ®Google Scholar
• Wang AY, Peng PD, Ehrhardt A, Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther 2004;15(4):405-13
   PubMed Web of Science ®Google Scholar
• Gavrilescu LC, Van Etten RA: Production of replication-defective retrovirus by transient transfection of 293T cells. J Vis Exp 2007;(10):550
   PubMedGoogle Scholar
• Swanson CM, Malim MH. Retrovirus RNA trafficking: from chromatin to invasive genomes. Traffic 2006;7(11):1440-50
   PubMed Web of Science ®Google Scholar
• Nair V. Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther 2008;10(5):431-8
   PubMed Web of Science ®Google Scholar
• Du Y, Spence SE, Jenkins NA, Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 2005;106(7):2498-505
   PubMed Web of Science ®Google Scholar
• Chinnasamy N, Shaffer J, Chinnasamy D. Production of multicistronic HIV-1 based lentiviral vectors. Methods Mol Biol 2009;515:137-50
   PubMedGoogle Scholar
• Howard BD, Boenicke L, Schniewind B, Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther 2000;7(6):927-38
   PubMed Web of Science ®Google Scholar
• Saraga G, Mafficini A, Ghaneh P, Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Ther 2007;14(9):781-90
   PubMed Web of Science ®Google Scholar
• Lewis BC, Klimstra DS, Varmus HE. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev 2003;17(24):3127-38
   PubMed Web of Science ®Google Scholar
• Mayr U, von Werder A, Seidler B, RCAS-mediated retroviral gene delivery: a versatile tool for the study of gene function in a mouse model of pancreatic cancer. Hum Gene Ther 2008;19(9):896-906
   PubMed Web of Science ®Google Scholar
• Seidler B, Schmidt A, Mayr U, A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci USA 2008;105(29):10137-42
   PubMed Web of Science ®Google Scholar
• Hirsch-Lerner D, Zhang M, Eliyahu H, Effect of "helper lipid" on lipoplex electrostatics. Biochim Biophys Acta 2005;1714(2):71-84
   PubMed Web of Science ®Google Scholar
• Kearns MD, Donkor AM, Savva M. Structure-transfection activity studies of novel cationic cholesterol-based amphiphiles. Mol Pharm 2008;5(1):128-39
   PubMed Web of Science ®Google Scholar
• Barteau B, Chèvre R, Letrou-Bonneval E, Physicochemical parameters of non-viral vectors that govern transfection efficiency. Curr Gene Ther 2008;8(5):313-23
   PubMed Web of Science ®Google Scholar
• Ahmad A, Evans HM, Ewert K, New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid-DNA complexes for gene delivery. J Gene Med 2005;7(6):739-48
   PubMed Web of Science ®Google Scholar
• Kodama K, Katayama Y, Shoji Y, The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 2006;13(18):2155-61
   PubMed Web of Science ®Google Scholar
• Zintchenko A, Philipp A, Dehshahri A, Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem 2008;19(7):1448-55
   PubMed Web of Science ®Google Scholar
• Akinc A, Thomas M, Klibanov AM, Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005;7(5):657-63
   PubMed Web of Science ®Google Scholar
• Sonawane ND, Szoka FC, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003;278(45):44826-31
   PubMed Web of Science ®Google Scholar
• Aoki K, Furuhata S, Hatanaka K, Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther 2001;8(7):508-14
   PubMed Web of Science ®Google Scholar
• Sharma VK, Thomas M, Klibanov AM. Mechanistic studies on aggregation of polyethylenimine-DNA complexes and its prevention. Biotechnol Bioeng 2005;90(5):614-20
   PubMed Web of Science ®Google Scholar
• Malek A, Merkel O, Fink L, In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 2009;236(1):97-108
   PubMed Web of Science ®Google Scholar
• Veiseh O, Kievit FM, Gunn JW, A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 2009;30(4):649-57
   PubMed Web of Science ®Google Scholar
• van der Aa MA, Koning GA, d'Oliveira C, An NLS peptide covalently linked to linear DNA does not enhance transfection efficiency of cationic polymer based gene delivery systems. J Gene Med 2005;7(2):208-17
   PubMed Web of Science ®Google Scholar
• Moffatt S, Wiehle S, Cristiano RJ. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther 2006;13(21):1512-23
   PubMed Web of Science ®Google Scholar
• Chang LW, Lue JT. Magnetic properties of multi-walled carbon nanotubes. J Nanosci Nanotechnol 2009;9(3):1956-63
   PubMed Web of Science ®Google Scholar
• Jin SH, Kang IH, Kim YS, Thermal and electrical properties of nanocomposites based on acrylic copolymers and multiwalled carbon nanotube. J Nanosci Nanotechnol 2008;8(10):5076-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Tu X, Welsher K, Optical characterizations and electronic devices of nearly pure (10,5) single-walled carbon nanotubes. J Am Chem Soc 2009;131(7):2454-5
   PubMed Web of Science ®Google Scholar
• Tan Y, Resasco DE. Dispersion of single-walled carbon nanotubes of narrow diameter distribution. J Phys Chem B 2005;109(30):14454-60
   PubMed Web of Science ®Google Scholar
• Fu K, Sun YP. Dispersion and solubilization of carbon nanotubes. J Nanosci Nanotechnol 2003;3(5):351-64
   PubMed Web of Science ®Google Scholar
• Dyke CA, Tour JM. Overcoming the insolubility of carbon nanotubes through high degrees of sidewall functionalization. Chemistry 2004;10(4):812-7
   PubMedGoogle Scholar
• Klumpp C, Kostarelos K, Prato M, Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006;1758(3):404-12
   PubMed Web of Science ®Google Scholar
• Singh R, Pantarotto D, McCarthy D, Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 2005;127(12):4388-96
   PubMed Web of Science ®Google Scholar
• Miyawaki J, Yudasaka M, Azami T, Toxicity of single-walled carbon nanohorns. ACS Nano 2008;2(2):213-26
   PubMed Web of Science ®Google Scholar
• Bellucci S, Chiaretti M, Cucina A, Multiwalled carbon nanotube buckypaper: toxicology and biological effects in vitro and in vivo. Nanomed 2009;4(5):531-40
   PubMed Web of Science ®Google Scholar
• Simeonova PP. Update on carbon nanotube toxicity. Nanomed 2009;4(4):373-5
   PubMed Web of Science ®Google Scholar
• Dumortier H, Lacotte S, Pastorin G, Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006;6(7):1522-8
   PubMed Web of Science ®Google Scholar
• Klumpp C, Kostarelos K, Prato M, Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006;1758(3):404-12
   PubMed Web of Science ®Google Scholar
• Singh R, Pantarotto D, Lacerda L, Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA 2006;103(9):3357-62
   PubMed Web of Science ®Google Scholar
• Singh R, Pantarotto D, McCarthy D, Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 2005;127(12):4388-96
   PubMed Web of Science ®Google Scholar
• Podesta JE, Al-Jamal KT, Herrero MA, Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009;5(10):1176-85
   PubMed Web of Science ®Google Scholar
• Yang F, Fu de L, Long J, Magnetic lymphatic targeting drug delivery system using carbon nanotubes. Med. Hypotheses 2008;70(4):765-7
   PubMed Web of Science ®Google Scholar
• Yang F, Hu J, Yang D, Pilot study of targeting magnetic carbon nanotubes to lymph nodes. Nanomed 2009;4(3):317-30
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Li Y, Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5(3):483-93
   PubMed Web of Science ®Google Scholar
• Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101(2):344-52
   PubMed Web of Science ®Google Scholar
• Guan HT, Xue XH, Dai ZJ, Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol 2006;12(18):2901-7
   PubMed Web of Science ®Google Scholar
• Fahy BN, Schlieman MG, Virudachalam S, Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004;198(4):591-9
   PubMed Web of Science ®Google Scholar
• Peng B, Fleming JB, Breslin T, Suppression of tumorigenesis and induction of p15ink4b by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002;8(11):3628-38
   PubMed Web of Science ®Google Scholar
• Rödicker F, Pützer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003;63(11):2737-41
   PubMed Web of Science ®Google Scholar
• Li Y, Qian H, Li X, Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell. J Gene Med 2009;11(1):3-13
   PubMed Web of Science ®Google Scholar
• Pirocanac EC, Nassirpour R, Yang M, Bax-induction gene therapy of pancreatic cancer. J Surg Res 2002;106(2):346-51
   PubMed Web of Science ®Google Scholar
• Pan XT, Zhu QY, Li DC, Effect of recombinant adenovirus vector mediated human interleukin-24 gene transfection on pancreatic carcinoma growth. Chin Med. J (Engl) 2008;121(20):2031-6
   PubMed Web of Science ®Google Scholar
• Park JK, Lee EJ, Esau C, Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009: published online 2 September 2009, doi: 10.1097/MPA.0b013e3181ba82e1
   Google Scholar
• Moriyama T, Ohuchida K, Mizumoto K, MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009: published online 12 May 2009, doi: 10.1158/1535-7163.MCT-08-0592
   Google Scholar
• Ji Q, Hao X, Zhang M, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4(8):e6816. Published online 28 August 2009, doi:10.1371/journal.pone.0006816
   PubMedGoogle Scholar
• Li Y, VandenBoom TG, Kong D, Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009;69(16):6704-12
   PubMed Web of Science ®Google Scholar
• Torrisani J, Bournet B, du Rieu MC, let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009;20(8):831-44
   PubMed Web of Science ®Google Scholar
• Lee KH, Lotterman C, Karikari C, Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009;9(3):293-301
   PubMed Web of Science ®Google Scholar